Gates Foundation Strategic Investment Fund Logo

Press Release: Arsanis Completes $45.5 Million Series D Financing

Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced the closing of a $45.5 million Series D financing led by the Bill & Melinda Gates Foundation. Several Read More